Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

E Dell'Aquila; C Cremolini; T Zeppola; S Lonardi; F Bergamo; G Masi; M Stellato; F Marmorino; M Schirripa; F Urbano; M Ronzoni; G Tomasello; A Zaniboni; P Racca; A Buonadonna; G Allegrini; E Fea; S Di Donato; S Chiara; G Tonini; D Tomcikova; L Boni; A Falcone; D Santini

doi:10.1093/annonc/mdy004

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

E Dell'Aquila, C Cremolini, T Zeppola, S Lonardi, F Bergamo, G Masi, M Stellato, F Marmorino, M Schirripa, F Urbano, M Ronzoni, G Tomasello, A Zaniboni, P Racca, A Buonadonna, G Allegrini, E Fea, S Di Donato, S Chiara, G ToniniD Tomcikova, L Boni, A Falcone, D Santini

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the prognostic and predictive role of NLR in the TRIBE trial.Patients and methods: Pts enrolled in TRIBE trial were included. TRIBE is a multicentre phase III trial randomizing unresectable and previously untreated mCRC pts to receive FOLFOXIRI or FOLFIRI plus bevacizumab. A cut-off value of 3 was adopted to discriminate pts with low (NLR

Original language	English
Pages (from-to)	924-930
Number of pages	7
Journal	Annals of Oncology
Volume	29
Issue number	4
DOIs	https://doi.org/10.1093/annonc/mdy004
Publication status	Published - Apr 1 2018

Access to Document

10.1093/annonc/mdy004

Cite this

Dell'Aquila, E., Cremolini, C., Zeppola, T., Lonardi, S., Bergamo, F., Masi, G., Stellato, M., Marmorino, F., Schirripa, M., Urbano, F., Ronzoni, M., Tomasello, G., Zaniboni, A., Racca, P., Buonadonna, A., Allegrini, G., Fea, E., Di Donato, S., Chiara, S., ... Santini, D. (2018). Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Annals of Oncology, 29(4), 924-930. https://doi.org/10.1093/annonc/mdy004

Dell'Aquila, E, Cremolini, C, Zeppola, T, Lonardi, S , Bergamo, F , Masi, G, Stellato, M, Marmorino, F, Schirripa, M, Urbano, F, Ronzoni, M, Tomasello, G, Zaniboni, A, Racca, P, Buonadonna, A, Allegrini, G, Fea, E, Di Donato, S, Chiara, S, Tonini, G, Tomcikova, D, Boni, L , Falcone, A & Santini, D 2018, 'Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO', Annals of Oncology, vol. 29, no. 4, pp. 924-930. https://doi.org/10.1093/annonc/mdy004

@article{3a834b0827314b57a2179950350ae5c0,

title = "Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO",

abstract = "Background: Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the prognostic and predictive role of NLR in the TRIBE trial.Patients and methods: Pts enrolled in TRIBE trial were included. TRIBE is a multicentre phase III trial randomizing unresectable and previously untreated mCRC pts to receive FOLFOXIRI or FOLFIRI plus bevacizumab. A cut-off value of 3 was adopted to discriminate pts with low (NLR ",

author = "E Dell'Aquila and C Cremolini and T Zeppola and S Lonardi and F Bergamo and G Masi and M Stellato and F Marmorino and M Schirripa and F Urbano and M Ronzoni and G Tomasello and A Zaniboni and P Racca and A Buonadonna and G Allegrini and E Fea and {Di Donato}, S and S Chiara and G Tonini and D Tomcikova and L Boni and A Falcone and D Santini",

year = "2018",

month = apr,

day = "1",

doi = "10.1093/annonc/mdy004",

language = "English",

volume = "29",

pages = "924--930",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "4",

}

TY - JOUR

T1 - Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

AU - Dell'Aquila, E

AU - Cremolini, C

AU - Zeppola, T

AU - Lonardi, S

AU - Bergamo, F

AU - Masi, G

AU - Stellato, M

AU - Marmorino, F

AU - Schirripa, M

AU - Urbano, F

AU - Ronzoni, M

AU - Tomasello, G

AU - Zaniboni, A

AU - Racca, P

AU - Buonadonna, A

AU - Allegrini, G

AU - Fea, E

AU - Di Donato, S

AU - Chiara, S

AU - Tonini, G

AU - Tomcikova, D

AU - Boni, L

AU - Falcone, A

AU - Santini, D

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the prognostic and predictive role of NLR in the TRIBE trial.Patients and methods: Pts enrolled in TRIBE trial were included. TRIBE is a multicentre phase III trial randomizing unresectable and previously untreated mCRC pts to receive FOLFOXIRI or FOLFIRI plus bevacizumab. A cut-off value of 3 was adopted to discriminate pts with low (NLR

AB - Background: Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the prognostic and predictive role of NLR in the TRIBE trial.Patients and methods: Pts enrolled in TRIBE trial were included. TRIBE is a multicentre phase III trial randomizing unresectable and previously untreated mCRC pts to receive FOLFOXIRI or FOLFIRI plus bevacizumab. A cut-off value of 3 was adopted to discriminate pts with low (NLR

U2 - 10.1093/annonc/mdy004

DO - 10.1093/annonc/mdy004

M3 - Article

SN - 0923-7534

VL - 29

SP - 924

EP - 930

JO - Annals of Oncology

JF - Annals of Oncology

IS - 4

ER -

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

Abstract

Access to Document

Fingerprint

Cite this